Description: ContraFect Corporation operates as a biotechnology company that focuses on development and commercialization of protein and antibody products for life-threatening, drug-resistant infectious diseases, and particularly those used in hospital-based settings. The company's product candidates are CF-301 and CF-302, the bacteriophage lysins for the treatment of staph aureus infections; and CF-404, a cocktail of monoclonal antibodies for the treatment of life-threatening seasonal and pandemic varieties of influenza. The company was founded in 2008 and is headquartered in Yonkers, New York.
Home Page: www.contrafect.com
CFRX Technical Analysis
28 Wells Avenue
Yonkers,
NY
10701
United States
Phone:
914 207 2300
Officers
| Name | Title |
|---|---|
| Dr. Roger James Pomerantz F.A.C.P., FACP, M.D. | Chairman, CEO & Pres |
| Mr. Michael Messinger CPA, CPA | Chief Financial Officer |
| Ms. Natalie Bogdanos J.D. | Gen. Counsel, Corp. Sec. & Data Protection Officer |
| Mr. Matthew Salamone P.H.R., SPHR | VP of HR |
| Dr. Gary Woodnutt | Sr. VP of Translational Sciences & Preclinical Devel. |
Exchange: NASDAQ
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.4405 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2014-07-29 |
| Fiscal Year End: | December |
| Full Time Employees: | 38 |